Onkologie 2020: 14(Suppl.B): 34-36 | DOI: 10.36290/xon.2020.033
Nivolumab-induced hepatitis in a patient treated for malignant melanoma
- 1 Onkologická a radioterapeutická klinika LF UK a FN Plzeň
- 2 I. interní klinika LF UK a FN Plzeň
Nivolumab is still relatively new modality of treatment that we use nowadays to treat many malignant diseases such as renal carcinoma, urotelial carcinoma, lung carcinoma as well as malignant melanoma. Despite its excellent treatment results it comes with a number of side effects such as skin rash, colitis, pneumonitis or hepatitis. Most of its side effects are well manageable and do not require permanent cessation of treatment. In this described case report we see relatively rare case of severe hepatopathy which did not respond to conventional immunosuppressive therapy and led to permanent cessation of nivolumab treatment. Diagnostic procedures, therapeutic judgment, and each line of immunosuppressive treatment as well as managing their side effects are discussed here. In the discussion the whole case report is commented and compared with data available in literature.
Keywords: nivolumab, hepatopathy, malignant melanoma, immunosuppression.
Published: June 2, 2020 Show citation
| ACS | AIP | APA | ASA | Harvard | Chicago | Chicago Notes | IEEE | ISO690 | MLA | NLM | Turabian | Vancouver |
References
- Guo L, Zhang H, Chen B. Nivolumab as programmed death-1 (PD-1) inhibitor for targeted immunotherapy in tumor. Journal of Cancer 2017; 8(3): 410.
Go to original source... 
Go to PubMed... - Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. New England journal of medicine, 2015; 372(4): 320-330. Go to original source... Go to PubMed...
- Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Annals of Oncology 2015; 26(12): 2375-2391. Go to original source... Go to PubMed...
- Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2017; 28(4): 119-142. Go to original source...
- Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. New England journal of medicine, 2015; 373(1): 23-34. Go to original source... Go to PubMed...
- Chmiel KD, Suan D, Liddle C, et al. Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. Journal of Clinical Oncology, 2011; 29(9): 237-240. Go to original source... Go to PubMed...
- Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. Journal of Clinical Oncology, 2012; 30(21): 2691-2697. Go to original source... Go to PubMed...
- Abdel-Rahman O, ElHalawani H, Fouad M. Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Expert opinion on drug safety, 2015; 14(10): 1507-1518. Go to original source... Go to PubMed...
- Zhang D, Hart J, Ding X, et al. Histologic patterns of liver injury induced by anti-PD-1 therapy. Gastroenterology Report 2019. Go to original source...
- Matsubara T, Nishida T, Higaki Y, et al. Nivolumab induces sustained liver injury in a patient with malignant melanoma. Internal Medicine, 2018; 57(12): 1789-1792. Go to original source... Go to PubMed...